Treatment for anxiety
Reading File
Finding Sources
Searching PubMed
anxiety disorders treatment pharmacotherapy psychotherapy
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive overview of anxiety disorder treatment, drawn from Kaplan & Sadock's Synopsis of Psychiatry, Goodman & Gilman's Pharmacological Basis of Therapeutics, and the Textbook of Family Medicine.
Treatment of Anxiety Disorders
General Principles
The primary goal of treatment is remission of all symptoms and restoration of baseline functioning. Treatment initiation should include:
- Patient education about the illness, prognosis, and treatment course
- Emphasis on sleep hygiene, regular exercise, nutrition, and social interaction
- Safety monitoring (especially if suicidal ideation is present)
- Measurement-based care with validated scales (e.g., GAD-7)
- Follow-up within 2–4 weeks of starting treatment
Meta-analyses show pharmacologic treatment has the largest effect size among available options, though combined pharmacotherapy + psychotherapy is superior to either alone.
Pharmacotherapy
First-Line: SSRIs & SNRIs
Selective serotonin reuptake inhibitors (SSRIs) are the first-line agents for most anxiety disorders, including:
- Generalized anxiety disorder (GAD)
- Panic disorder
- Social anxiety disorder
- PTSD and OCD (with exceptions)
SNRIs (e.g., venlafaxine) are also effective for GAD, panic disorder, and social anxiety disorder.
- Allow 8–12 weeks at optimal dose before assessing efficacy
- Maintenance treatment for at least 6 months is evidence-backed
- Onset of improvement typically 3–6 weeks
Second-Line Agents
| Drug Class | Notes |
|---|---|
| TCAs (tricyclic antidepressants) | Effective for panic disorder; less preferred due to side-effect profile |
| Mirtazapine | Useful due to sedative effect; limited formal studies in anxiety |
| Buspirone | Particularly for GAD; non-sedating, non-habit-forming; delayed onset ~2–4 weeks |
| Benzodiazepines | Highly effective short-term; limit to acute use or adjunct to SSRIs during initiation |
| Beta-blockers | Used for situational (performance) anxiety |
| MAOIs | Effective but rarely used due to dietary restrictions and drug interactions |
Benzodiazepine note: Most guidelines recommend limiting these to short-term use — either as an adjunct during the initial SSRI treatment phase or for acute exacerbations. Long-term monotherapy is generally discouraged due to dependence risk.
Psychotherapy
Cognitive-Behavioral Therapy (CBT)
The most evidence-based psychotherapeutic approach. Includes techniques such as:
- Cognitive restructuring
- Exposure and response prevention (especially for OCD/specific phobias)
- Relaxation training
- Panic control therapy
CBT is as effective as medication for mild-to-moderate anxiety and provides more durable benefits with lower relapse rates.
Other Psychotherapies
| Modality | Key Feature |
|---|---|
| Behavioral therapy | Systematic desensitization, graded exposure, flooding, thought-stopping |
| Interpersonal psychotherapy (IPT) | Good evidence, especially for social anxiety disorder |
| Insight-oriented/psychodynamic | Targets underlying conflicts; less empirical support but may have lasting effects |
| Supportive psychotherapy | Frequently used as an adjunct; promotes adaptive coping |
| Virtual/exposure therapy | Computer-simulated environments (e.g., for agoraphobia, flying phobia) |
Disorder-Specific Highlights
| Disorder | Preferred Treatment |
|---|---|
| GAD | SSRIs, SNRIs (venlafaxine), buspirone; CBT |
| Panic disorder | SSRIs, TCAs, venlafaxine; CBT + exposure |
| Social anxiety disorder | SSRIs, venlafaxine, clonazepam (adjunct); IPT, CBT |
| Specific phobia | Graded exposure therapy (first-line); medication rarely indicated |
| PTSD | SSRIs (sertraline, paroxetine FDA-approved); trauma-focused CBT |
| OCD | SSRIs at higher doses; CBT with ERP |
When to Refer / Hospitalize
- Psychotic features → refer to psychiatry; may require antipsychotics ± ECT
- Comorbid substance use disorder
- Suicidal ideation with intent or plan
- Failure of two adequate pharmacologic trials
Sources: Kaplan & Sadock's Synopsis of Psychiatry; Goodman & Gilman's The Pharmacological Basis of Therapeutics; Textbook of Family Medicine 9e
Disclaimer: This information is for educational purposes. Treatment decisions should always be individualized and made in consultation with a qualified healthcare provider.
Inj pantop dosage
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a concise, evidence-based dosing reference for Injection Pantoprazole (IV):
Inj. Pantoprazole — IV Dosage
Adults
| Indication | Dose |
|---|---|
| GERD / acid suppression (routine) | 40 mg IV once daily |
| Upper GI bleed — acute bolus | 80 mg IV over 15–30 min |
| Upper GI bleed — continuous infusion (after bolus, following endoscopic hemostasis) | 8 mg/hour for 72 hours |
| Zollinger-Ellison / hypersecretory states | 80 mg IV every 8–12 hours (titrated to acid output) |
After 72 hours of infusion, switch to oral PPI 40 mg once daily.
Pediatric (Weight-Based) — Upper GI Bleed
| Weight | Bolus Dose | Infusion Rate |
|---|---|---|
| 5–15 kg | 2 mg/kg/dose IV | 0.2 mg/kg/h IV |
| 15–40 kg | 1.8 mg/kg/dose IV | 0.18 mg/kg/h IV |
| >40 kg | 80 mg IV (fixed) | 8 mg/h IV |
Administration Notes
- Reconstitution: Dilute in NS or D5W; infuse bolus dose over 15 minutes (some protocols allow 2-min rapid IV)
- Fasting patients: IV pantoprazole only inhibits actively secreting pumps — continuous infusion or repeated bolus is needed for maximal acid suppression in the first 24–48 hours
- Renal impairment: No dose adjustment needed
- Hepatic impairment: No adjustment for mild–moderate; consider dose reduction in severe hepatic impairment
- Drug should be given 30–60 minutes before meals when transitioning to oral form
Key Clinical Point
High-dose IV PPI (80 mg bolus → 8 mg/h infusion) after successful endoscopic hemostasis reduces rebleeding rates and mortality in peptic ulcer bleeding with high-risk stigmata.
Sources: Goldman-Cecil Medicine; Katzung's Basic & Clinical Pharmacology 16e; Tintinalli's Emergency Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics
Tab clonazepam 0.5 mg for anxiety
Finding Sources
Reading File
Reading File
Here is a complete prescribing reference for Tab Clonazepam 0.5 mg for Anxiety:
Tab Clonazepam 0.5 mg — Anxiety
Dosing
| Indication | Dose | Frequency |
|---|---|---|
| Acute anxiety / GAD | 0.5–1 mg | Once or twice daily, as needed |
| Panic disorder | 0.5 mg | Twice daily; may titrate up to 1–2 mg/day |
| Social anxiety disorder | 0.5–2 mg | Once or twice daily |
| Maximum dose (anxiety) | 4 mg/day | Divided doses |
- Starting dose: 0.5 mg once or twice daily is appropriate as an initiation dose
- Titration: Increase gradually by 0.5 mg every 3 days based on response and tolerability
- Preferred over shorter-acting BZDs (e.g., alprazolam) because of its longer half-life (~18–50 hrs) → less interdose rebound anxiety, once or twice daily dosing sufficient
Advantages Over Other Benzodiazepines
- Longer half-life → smoother, more even anxiolysis throughout the day
- Less risk of interdose rebound anxiety compared to alprazolam or lorazepam
- FDA-approved for panic disorder
- Can be dosed once daily at night (reducing daytime sedation)
Important Prescribing Cautions
| Issue | Detail |
|---|---|
| Duration | Limit to ≤4 weeks for anxiety; risk of dependence with prolonged use |
| Tapering | Must be tapered gradually on discontinuation — abrupt withdrawal can cause seizures |
| Sedation | Common, especially at initiation; warn patients not to drive |
| Elderly | Higher risk of falls, cognitive impairment, fractures — use with caution; start low |
| Substance use history | Avoid or use with close monitoring in patients with addiction history |
| Memory impairment | Anterograde amnesia risk, especially at higher doses |
| Not for chronic use alone | SSRIs/SNRIs are first-line for long-term anxiety management; clonazepam is best used as a bridge during SSRI initiation or for PRN/acute use |
Role in Treatment Strategy
Acute/short-term anxiety: Clonazepam 0.5 mg BD × 2–4 weeks
Long-term anxiety management: SSRI (e.g., sertraline, escitalopram) ± clonazepam as bridge
Panic disorder: Clonazepam + SSRI (combined approach)
Sources: Textbook of Family Medicine 9e; Dermatology 5e; Kaplan & Sadock's Synopsis of Psychiatry
Note: Benzodiazepines are not recommended as long-term monotherapy for anxiety. Always pair with a definitive treatment plan (SSRI/CBT) and set clear expectations regarding duration and refill limits.
This is a shared conversation. Sign in to Orris to start your own chat.